Premature Ejaculation Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, and Zertane), By Type (Oral Therapies and Topical Therapies), By Dosage Form (Pills and Spray), By Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

1.33 billion

CAGR (2023-2028)

7.40%

Fastest Growing Segment

Online Pharmacies 

Largest Market

North America

 

Market Overview

Global Premature Ejaculation Treatment Market has valued at USD 1.33 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.40% through 2028.   Premature ejaculation (PE) is a common sexual dysfunction that occurs when a man ejaculates (releases semen) shortly after sexual activity begins and before he or his partner desires it. PE is characterized by a lack of control over ejaculation, resulting in rapid or uncontrolled ejaculation that can interfere with sexual satisfaction and intimacy. It is one of the most prevalent sexual concerns among men. The exact causes of PE can be complex and include a combination of physical, psychological, and behavioral factors. Possible causes include anxiety, stress, relationship issues, hypersensitivity of the penis, and certain medical conditions. PE can have a significant impact on the affected individual and their partner. It can lead to frustration, embarrassment, and reduced sexual satisfaction. Relationship problems may also arise due to the challenges posed by PE. PE is typically diagnosed based on a thorough medical and sexual history, including discussions about the timing of ejaculation and any contributing factors. Physical exams or laboratory tests are not usually necessary for diagnosis.

The widespread occurrence of premature ejaculation as one of the most common sexual dysfunctions among men creates a substantial patient pool seeking treatment options. Growing awareness of sexual health issues and the availability of treatments has encouraged more individuals to seek help for premature ejaculation, driving demand for treatment options. Ongoing research and development by pharmaceutical companies have led to the creation of new medications specifically designed to treat premature ejaculation, expanding the range of available treatment options. The effectiveness of behavioral therapies, such as cognitive-behavioral therapy (CBT) and sex therapy, in addressing premature ejaculation has encouraged their adoption as treatment methods. In some regions, health insurance plans may cover the cost of prescription medications for premature ejaculation, making treatment more accessible to a broader population.

Key Market Drivers

Rising Pharmaceutical Innovation

Pharmaceutical companies invest in research and development to create medications that are specifically designed to treat premature ejaculation. These medications are formulated to address the underlying causes of PE, such as serotonin reuptake inhibitors (SSRIs) like dapoxetine. The availability of these specialized drugs provides effective and targeted treatment options for individuals suffering from PE. Pharmaceutical innovation aims to improve the efficacy of premature ejaculation treatments. New medications are developed to better control ejaculation timing, thereby enhancing treatment outcomes and patient satisfaction. Improved effectiveness encourages more individuals to seek treatment. Pharmaceutical companies work to develop medications with fewer side effects or adverse reactions. Reducing side effects can enhance patient compliance and comfort, as individuals may be more willing to use treatments that have minimal impact on their daily lives and well-being. Pharmaceutical innovation involves rigorous clinical trials and research to demonstrate the safety and efficacy of new PE treatments. These studies provide scientific evidence of treatment effectiveness, which can build trust among healthcare providers and patients.

Ongoing pharmaceutical innovation leads to the introduction of a variety of treatment options, including oral medications, topical creams, and other formulations. This diversity allows healthcare providers to tailor treatments to individual patient needs and preferences. Competition among pharmaceutical companies drives innovation. Companies strive to develop better and more effective treatments to gain a competitive edge in the PE treatment market. This competition can result in a wider selection of treatment options for patients. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), evaluate and approve new medications for premature ejaculation. These approvals validate the safety and efficacy of the treatments, increasing their acceptance among healthcare providers and patients. Pharmaceutical innovations often lead to the global availability of PE treatments. As medications receive approvals and become available in multiple countries, individuals worldwide can access these treatments, further driving demand. Pharmaceutical companies invest in educational initiatives to increase awareness about premature ejaculation and available treatments. These efforts empower individuals to recognize the condition and seek appropriate care. Pharmaceutical companies collaborate with healthcare providers to promote their products, provide training, and offer educational resources. These partnerships can enhance the knowledge and confidence of healthcare professionals in recommending PE treatments. This factor will help in the development of the Global Premature Ejaculation Treatment Market.

High Prevalence of Premature Ejaculation

The prevalence of premature ejaculation is relatively high, with estimates suggesting that it affects a substantial portion of the male population. As a result, there is a large and potentially underserved patient population seeking treatment for PE. As more individuals become aware of premature ejaculation as a common sexual dysfunction, they are more likely to seek help. High prevalence contributes to discussions around PE, reducing stigma, and encouraging individuals to acknowledge the issue and pursue treatment. Premature ejaculation can significantly affect an individual's quality of life and relationships. The distress and frustration experienced by those with PE motivate them to seek solutions and improve their sexual well-being. PE can strain relationships, leading affected individuals and their partners to actively seek treatment options that can enhance sexual satisfaction and relationship harmony. The emotional toll of PE, including anxiety, depression, and low self-esteem, can drive individuals to seek professional help. Effective treatment can address both the physical and psychological aspects of the condition.

Partners of individuals with PE may also play a role in encouraging them to seek treatment. Partners often have a vested interest in finding solutions to improve sexual satisfaction and intimacy. As the global population ages, the prevalence of sexual health issues, including PE, tends to increase. Older individuals are more likely to experience sexual dysfunctions, driving demand for treatment options. Information about premature ejaculation and available treatments is readily accessible through various media channels, including the internet, print, and television. This increased exposure encourages individuals to explore treatment options. Individuals often seek guidance from healthcare providers, who may recommend premature ejaculation treatment based on the patient's symptoms and concerns. The high prevalence of PE prompts healthcare providers to be proactive in discussing treatment options with their patients. Support groups and online communities for individuals with PE provide a platform for sharing experiences and treatment recommendations, further motivating individuals to seek help. The demand for PE treatments has spurred growth in the development and availability of various treatment options, including pharmaceuticals, behavioral therapies, topical treatments, and medical devices. This growth reflects the high demand for effective solutions. This factor will pace up the demand of the Global Premature Ejaculation Treatment Market.

Increasing Demand of Behavioral Therapies

Behavioral therapies offer a non-invasive and drug-free approach to treating premature ejaculation. Many individuals prefer non-pharmacological treatments due to concerns about potential side effects or drug interactions, which drives the demand for these therapies. Behavioral therapies, such as the "Start-Stop" technique, the "Squeeze" technique, and pelvic floor exercises, have been found to be effective in improving ejaculatory control and delaying ejaculation. Positive outcomes and success stories from individuals who have undergone these therapies encourage others to seek similar treatments. Behavioral therapies empower individuals to take an active role in managing their premature ejaculation. Patients learn techniques and strategies that they can apply themselves or with their partners, which can lead to a sense of control and confidence. Behavioral therapies often focus on addressing the underlying causes and triggers of premature ejaculation. This results in potential long-term benefits, as individuals can acquire skills and strategies to manage their condition effectively over time. Many behavioral therapies take a holistic approach to sexual health, addressing not only the physical aspects of premature ejaculation but also the psychological and emotional factors that may contribute to the condition. This comprehensive approach resonates with individuals seeking a more holistic solution. Behavioral therapies can be conducted in the privacy of one's home, making them a discreet option for addressing premature ejaculation. This appeals to individuals who value confidentiality.

The availability and effectiveness of behavioral therapies help reduce the stigma associated with premature ejaculation. Open discussions about non-invasive treatment options contribute to a more supportive environment for individuals seeking help. Behavioral therapies do not rely on medications or topical products, making them suitable for individuals who prefer not to use such substances or who may have contraindications to certain medications. Behavioral therapies can be taught by healthcare providers or sexual health specialists, but they can also be accessed through online resources, books, and educational materials. This accessibility makes it easier for individuals to learn and implement these techniques. Behavioral therapies can be used in conjunction with other treatment modalities, such as medications or topical treatments, offering a multi-faceted approach to addressing premature ejaculation. The emphasis on patient education in behavioral therapies helps individuals understand the physiological and psychological aspects of premature ejaculation, enabling them to make informed decisions about their treatment options. This factor will accelerate the demand of the Global Premature Ejaculation Treatment Market.


Download Free Sample Report

Key Market Challenges

Side Effects and Safety Concerns

Many pharmaceutical treatments for premature ejaculation, such as selective serotonin reuptake inhibitors (SSRIs) like dapoxetine, may have side effects. Common side effects can include nausea, dizziness, headache, and potential sexual side effects like reduced libido or erectile dysfunction. These side effects can affect patient compliance and satisfaction. Responses to medications vary from person to person. What works well for one individual may not work as effectively or may have different side effects for another. Finding the right medication and dosage can be a trial-and-error process, which can be frustrating for both patients and healthcare providers. Some individuals may have underlying medical conditions, take medications, or have other factors that contraindicate the use of specific premature ejaculation treatments. Ensuring the safety of treatments for all patient populations can be a challenge. Premature ejaculation medications can interact with other medications a person may be taking for different health conditions. Healthcare providers need to carefully consider potential drug interactions to avoid adverse effects. The long-term safety of certain medications for premature ejaculation is not always well-established. Concerns about the prolonged use of these medications may deter some individuals from seeking or continuing treatment. While topical anesthetics like lidocaine creams can be effective in delaying ejaculation, there is a risk of reduced sensation, which can impact sexual pleasure for both partners. Balancing effectiveness with sensory enjoyment can be a challenge.

Stigma and Underreporting

Stigma and embarrassment related to sexual health issues, including premature ejaculation (PE), can deter individuals from seeking treatment. The reluctance to openly discuss and address these concerns can result in delayed or no treatment-seeking behavior. Due to the stigma associated with sexual health problems, many individuals may not even be aware that effective treatments for PE exist. This lack of awareness can contribute to underreporting and underdiagnosis of the condition. Patients may hesitate to discuss their sexual health concerns with healthcare providers due to fear of judgment or embarrassment. As a result, healthcare providers may not have accurate information about the prevalence and severity of PE among their patients. PE can strain intimate relationships, leading to communication challenges and decreased sexual satisfaction. Individuals and couples may choose to cope with the issue privately rather than seeking professional help, exacerbating the problem. Some individuals attempt to address PE through self-treatment methods, such as using over-the-counter products or online remedies. While these approaches may be convenient, they may not always be effective or safe, and they may contribute to underreporting to healthcare providers. Cultural norms and societal expectations can further contribute to the stigma surrounding PE. In some cultures, discussing sexual health openly remains taboo, making it even more challenging for individuals to seek help. Untreated PE can lead to psychological distress, including anxiety and depression, which can exacerbate the stigma. These mental health challenges may also go unreported and untreated

Key Market Trends

Patient-Centric Approach

 Healthcare providers are increasingly adopting a patient-centric approach by creating personalized treatment plans for individuals with PE. These plans consider factors such as the severity of PE, underlying causes, medical history, and patient preferences. Patients are encouraged to actively participate in the decision-making process regarding their treatment. Healthcare providers engage in open and collaborative discussions with patients to choose the most suitable treatment option based on the patient's goals and comfort level. Patient-centric care places a strong emphasis on patient education and counseling. Healthcare providers take the time to explain the condition, treatment options, potential side effects, and expected outcomes. This helps patients make informed choices about their treatment. The patient-centric approach recognizes that premature ejaculation can have physical, psychological, and emotional components. As a result, treatment plans may include a holistic approach that addresses these various aspects of the condition. Patients receive individualized follow-up care and support to monitor treatment progress and make necessary adjustments. This ensures that the chosen treatment aligns with the patient's evolving needs and goals. Telemedicine and remote monitoring technologies enable patients to access care from the comfort of their homes. This approach improves convenience and accessibility while maintaining a patient-centric focus. Patient preferences, including treatment modality and comfort with certain therapies, are respected. Providers work with patients to find treatments that align with their preferences and lifestyles.

Segmental Insights

Drug Type Insights

In 2022, the Global Premature Ejaculation Treatment Market largest share was held by Topical Anesthetics segment and is predicted to continue expanding over the coming years. Topical anesthetics are typically applied directly to the penis before sexual activity, offering a discreet and easy-to-use option for addressing premature ejaculation. Some individuals may prefer topical treatments over oral medications or behavioural therapies due to personal preferences or concerns about potential side effects. Topical anesthetics are designed to reduce penile sensitivity, which can help delay ejaculation. If these products are perceived as effective by both healthcare professionals and patients, they may capture a significant share of the market. Some topical anesthetics for premature ejaculation are available over the counter (OTC) without a prescription. This accessibility can make them a popular choice among individuals seeking self-treatment. Healthcare providers and pharmacists may educate patients on the proper use of topical anesthetics, increasing awareness and utilization.

Type Insights

In 2022, the Global Premature Ejaculation Treatment Market largest share was held by Oral Therapies segment and is predicted to continue expanding over the coming years.  Oral therapies for premature ejaculation often require a prescription from a healthcare provider. This means that patients may consult with physicians, urologists, or sexual health specialists, leading to higher visibility and utilization of oral treatments. Positive results from clinical studies and research on the safety and efficacy of oral therapies can contribute to their adoption and market dominance. Some individuals may prefer oral therapies over other treatment options, such as topical products or behavioural therapies. The convenience of taking a medication orally may appeal to many patients. Effective marketing and promotion strategies by pharmaceutical companies and healthcare providers can play a significant role in the success of oral therapies.

Dosage Form Insights

In 2022, the Global Premature Ejaculation Treatment Market largest share was held by Spray segment and is predicted to continue expanding over the coming years.  Premature ejaculation sprays can offer a discreet way to address the issue, as they are typically applied topically and do not require the same level of visibility as other treatment methods. Many individuals may prefer non-invasive treatments like sprays over other options, such as medications or medical devices, which may have more side effects or involve more invasive procedures. Premature ejaculation sprays can offer a discreet way to address the issue, as they are typically applied topically and do not require the same level of visibility as other treatment methods.

Distribution Channel, Insights

In 2022, the Global Premature Ejaculation Treatment Market largest share was held by Retail Pharmacies segment in the forecast period and is predicted to continue expanding over the coming years.  Retail pharmacies offer convenient access to a wide range of healthcare products, including premature ejaculation treatments. Individuals can visit these pharmacies to purchase both over the counter (OTC) and prescription medications, making them a primary distribution channel for these products. Many premature ejaculation treatments, especially prescription medications, require a healthcare provider's prescription. Retail pharmacies serve as crucial points of distribution for prescription drugs, ensuring that patients can access these treatments through authorized channels. Healthcare providers, including urologists, general practitioners, and sexual health specialists, often recommend or prescribe premature ejaculation treatments to patients. Patients typically fill these prescriptions at retail pharmacies, leading to increased sales in this segment. Retail pharmacies are typically located in accessible locations, making it easy for patients to visit and obtain their prescribed medications or seek advice from pharmacists regarding OTC options.

Download Free Sample Report

Regional Insights

The North America region dominates the Global Premature Ejaculation Treatment Market in 2022. North America, particularly the United States and Canada, has a well-developed healthcare infrastructure and a high level of awareness about sexual health issues, including premature ejaculation. This leads to more individuals seeking medical advice and treatment. The region is home to many pharmaceutical companies that develop and market drugs for premature ejaculation. These companies have the resources and expertise to conduct clinical trials, obtain regulatory approvals, and market their products effectively. North America has a robust clinical research environment, including academic institutions and research centers. This facilitates the study of new treatments and therapies for premature ejaculation, leading to innovation and advancements in the field. Many individuals in North America have health insurance that covers prescription medications, making it more affordable for them to access pharmaceutical treatments for premature ejaculation.

Recent Developments

  • In May 2018, Prolong revealed its plans to introduce the inaugural FDA-cleared climax control training program to the United States. This announcement coincides with recent research indicating that half of all men, or one in two, believe they experience premature ejaculation (PE). Prolong is categorized as a Class II vibrating medical device according to FDA classification. It forms an integral part of a program aimed at controlling premature ejaculation in males. The device is engineered to extend the duration between arousal and ejaculation by utilizing stimulating vibrations on the penis during training sessions, employing the Start-Stop technique. Prolong provides an affordable, painless treatment option, whether for a single use or long-term use, and it is free from any associated side effects. During testing, the Prolong™ prototype demonstrated an impressive efficacy level, surpassing the combined efficacy of the Start-Stop technique and behavioural therapy, which currently stands as the gold standard treatment for premature ejaculation. In a clinical trial conducted in Finland involving individuals who had struggled with lifelong premature ejaculation, 70% of the patients, even those who had previously failed all available treatments, including drug therapy, showed improvement after receiving Prolong™ treatment. Furthermore, these positive outcomes were either maintained or continued to improve six months following the completion of the treatment.
  • In October 2022, Morari, an innovative company focused on sexual health and wellness, has unveiled its equity-based community round campaign through the investment platform Wefunder. This initiative aims to secure funding for the final stages of product development, gain regulatory clearance, and prepare for the upcoming launch of its groundbreaking Mor patch. Remarkably, within just a few days of its commencement, the campaign has already surpassed 50 percent of its initial funding target. Morari was established with the primary objective of alleviating the challenges posed by premature ejaculation, which can cause significant distress for men and their partners. This condition is the most prevalent male sexual dysfunction, impacting approximately 30 percent of men. Additionally, there is a substantial 40 percent of men who may not meet the formal criteria for premature ejaculation but still desire to prolong their endurance during sexual activity.

Key Market Players

  • Absorption Pharmaceuticals Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Innovus Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

By Drug Type

By Type

By Dosage Form

By Distribution Channel

By Region

By Region
  • Dapoxetine
  • Phosphodiesterase Type 5 (PDE5) Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Topical Anesthetics
  • Zertane
  • Oral Therapies
  • Topical Therapies
  • Pills
  • Spray

  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East

 

Report Scope:

In this report, the Global Premature Ejaculation Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     Premature Ejaculation Treatment Market, By Drug Type:

o   Dapoxetine

o   Phosphodiesterase Type 5 (PDE5) Inhibitors

o   Selective Serotonin Reuptake Inhibitors

o   Topical Anesthetics

o   Zertane

 

  •   Premature Ejaculation Treatment Market, By Type:

 

o   Oral Therapies

§  Nonselective Serotonin Reuptake Inhibitor

§  Selective Serotonin Reuptake Inhibitor

o   Topical Therapies

  • Global Premature Ejaculation Treatment Market, By Dosage Form:

o   Pills

o   Spray

  •     Premature Ejaculation Treatment Market, By Distribution Channel:

o   Hospitals

o   Online Pharmacies

o   Retail Pharmacies

  • Global Premature Ejaculation Treatment Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premature Ejaculation Treatment Market.

Available Customizations:

Global Premature Ejaculation Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Premature Ejaculation Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Premature Ejaculation Treatment Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, and Zertane)

5.2.2.        By Type (Oral Therapies and Topical Therapies)

5.2.3.        By Dosage Form (Pills and Spray)

5.2.4.        By Distribution Channel (Hospitals, Online Pharmacies, and Retail Pharmacies)

5.2.5.        By Region

5.2.6.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific Premature Ejaculation Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Drug Type

6.2.2.        By Type

6.2.3.        By Dosage Form

6.2.4.        By Distribution Channel

6.2.5.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China Premature Ejaculation Treatment Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Drug Type

6.3.1.2.2.           By Type

6.3.1.2.3.           By Dosage Form

6.3.1.2.4.           By Distribution Channel

6.3.2.        India Premature Ejaculation Treatment Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Drug Type

6.3.2.2.2.           By Type

6.3.2.2.3.           By Dosage Form

6.3.2.2.4.           By Distribution Channel

6.3.3.        Australia Premature Ejaculation Treatment Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Drug Type

6.3.3.2.2.           By Type

6.3.3.2.3.           By Dosage Form

6.3.3.2.4.           By Distribution Channel

6.3.4.        Japan Premature Ejaculation Treatment Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Drug Type

6.3.4.2.2.           By Type

6.3.4.2.3.           By Dosage Form

6.3.4.2.4.           By Distribution Channel

6.3.5.        South Korea Premature Ejaculation Treatment Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Drug Type

6.3.5.2.2.           By Type

6.3.5.2.3.           By Dosage Form

6.3.5.2.4.           By Distribution Channel

7.    Europe Premature Ejaculation Treatment Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Drug Type

7.2.2.        By Type

7.2.3.        By Dosage Form

7.2.4.        By Distribution Channel

7.2.5.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France Premature Ejaculation Treatment Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Drug Type

7.3.1.2.2.           By Type

7.3.1.2.3.           By Dosage Form

7.3.1.2.4.           By Distribution Channel

7.3.2.        Germany Premature Ejaculation Treatment Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Drug Type

7.3.2.2.2.           By Type

7.3.2.2.3.           By Dosage Form

7.3.2.2.4.           By Distribution Channel

7.3.3.        Spain Premature Ejaculation Treatment Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Drug Type

7.3.3.2.2.           By Type

7.3.3.2.3.           By Dosage Form

7.3.3.2.4.           By Distribution Channel

7.3.4.        Italy Premature Ejaculation Treatment Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Drug Type

7.3.4.2.2.           By Type

7.3.4.2.3.           By Dosage Form

7.3.4.2.4.           By Distribution Channel

7.3.5.        United Kingdom Premature Ejaculation Treatment Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Drug Type

7.3.5.2.2.           By Type

7.3.5.2.3.           By Dosage Form

7.3.5.2.4.           By Distribution Channel

8.    North America Premature Ejaculation Treatment Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Drug Type

8.2.2.        By Type

8.2.3.        By Dosage Form

8.2.4.        By Distribution Channel

8.2.5.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States Premature Ejaculation Treatment Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Drug Type

8.3.1.2.2.           By Type

8.3.1.2.3.           By Dosage Form

8.3.1.2.4.           By Distribution Channel

8.3.2.        Mexico Premature Ejaculation Treatment Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Drug Type

8.3.2.2.2.           By Type

8.3.2.2.3.           By Dosage Form

8.3.2.2.4.           By Distribution Channel

8.3.3.        Canada Premature Ejaculation Treatment Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Drug Type

8.3.3.2.2.           By Type

8.3.3.2.3.           By Dosage Form

8.3.3.2.4.           By Distribution Channel

9.    South America Premature Ejaculation Treatment Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Drug Type

9.2.2.        By Type

9.2.3.        By Dosage Form

9.2.4.        By Distribution Channel

9.2.5.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil Premature Ejaculation Treatment Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Drug Type

9.3.1.2.2.           By Type

9.3.1.2.3.           By Dosage Form

9.3.1.2.4.           By Distribution Channel

9.3.2.        Argentina Premature Ejaculation Treatment Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Drug Type

9.3.2.2.2.           By Type

9.3.2.2.3.           By Dosage Form

9.3.2.2.4.           By Distribution Channel

9.3.3.        Colombia Premature Ejaculation Treatment Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Drug Type

9.3.3.2.2.           By Type

9.3.3.2.3.           By Dosage Form

9.3.3.2.4.           By Distribution Channel

10. Middle East and Africa Premature Ejaculation Treatment Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Drug Type

10.2.2.     By Type

10.2.3.     By Dosage Form

10.2.4.     By Distribution Channel

10.2.5.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Premature Ejaculation Treatment Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Type

10.3.1.2.2.         By Type

10.3.1.2.3.         By Dosage Form

10.3.1.2.4.         By Distribution Channel

10.3.2.     Saudi Arabia Premature Ejaculation Treatment Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Type

10.3.2.2.2.         By Type

10.3.2.2.3.         By Distribution Channel

10.3.3.     UAE Premature Ejaculation Treatment Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Type

10.3.3.2.2.         By Type

10.3.3.2.3.         By Dosage Form

10.3.3.2.4.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Premature Ejaculation Treatment Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Absorption Pharmaceuticals Inc.

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Allergan PLC

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   AstraZeneca PLC

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Bayer AG

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   Eli Lilly and Company

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   GlaxoSmithKline PLC

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Innovus Pharmaceuticals Inc.

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   Merck & Co., Inc.

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   Pfizer, Inc.

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.Teva Pharmaceutical Industries Ltd.

16.10.1.  Business Overview

16.10.2.  Company Snapshot

16.10.3.  Products & Services

16.10.4.  Financials (In case of listed companies)

16.10.5.  Recent Developments

16.10.6.  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Premature Ejaculation Treatment Market was estimated to be USD 3.00 billion in 2022.

down-arrow

Pfizer, Inc., Teva Pharmaceutical Industries Ltd. are some of the key players operating in the Premature Ejaculation Treatment Market.

down-arrow

Some treatments for premature ejaculation can be expensive, especially when considering ongoing medication or therapy sessions.

down-arrow

Non-pharmaceutical treatments such as cognitive-behavioral therapy (CBT) and psychotherapy have gained popularity.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Premature Ejaculation Treatment Market to grow with a CAGR of 8.90%

Nov, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Premature Ejaculation Treatment Market.

Why Choose Us